|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS MAY ANTAGONISE THE HYPOTENSIVE EFFECTS OF METHYLDOPA
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ADRENALINE & SIMILAR DRUGS MAY ENHANCE THE CARDIAC SIDE EFFECTS OF LEVODOPA
|
AMPHETAMINES CAN ENHANCE THE ACTIVITY OF SYMPATHOMIMETIC AGENTS
|
AMPHETAMINES CAN ENHANCE THE ACTIVITY OF SYMPATHOMIMETIC AGENTS
|
AMPHETAMINES CAN ENHANCE THE ACTIVITY OF SYMPATHOMIMETIC AGENTS
|
AMPHETAMINES CAN ENHANCE THE ACTIVITY OF SYMPATHOMIMETIC AGENTS
|
AMPHETAMINES CAN ENHANCE THE ACTIVITY OF SYMPATHOMIMETIC AGENTS
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS ARRHYTHMOGENIC EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS ARRHYTHMOGENIC EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS ARRHYTHMOGENIC EFFECT IS POTENTIATED BY THE DRUG
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|